

Product Data Sheet

Product Name: PZ703b TFA

Cat. No.: GC72863

Chemical Properties

Cas. No.

Formula $C_{82}H_{103}ClF_6N_{10}O_{13}S_4$

M.Wt 1714.46


Solubility

Storage -20°C, protect from light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

PZ703b TFA is a Bcl-xL PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research.

PZ703b (0-1 μ M, 24 h) TFA can synergistically inhibit bladder cancer cell proliferation with Mivebresib in a dose-dependent manner and induce apoptosis in bladder cancer cells via the mitochondrial pathway[1]. PZ703b (0-1 μ M, 48 h) TFA inhibits MOLT-4 and RS4;11 cells with the IC₅₀ values of 15.9 and 11.3 nM respectively[2]. PZ703b (10 nM, 48 h) TFA induces rapid and durable BCL-XL degradation and apoptosis in MOLT-4 cells through the caspase-3 mediated

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

pathway[2].

References:

- [1]. Yi Xu, et al. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Biochem Biops Res Commun. 2022 Oct 1;623:120-126.
- [2]. Pratik Pal, et al. Discovery of a Novel BCL-XLPROTAC Degradation with Enhanced BCL-2 Inhibition. J Med Chem. 2021 Oct 14;64(19):14230-14246.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA